Development of AGC Biologics amplification plasmid DNA


       SEATTLE Dec.12,2019/ Mercom/-- AGC Biologics, a global contract development and production agency for biopharmaceuticals, is significantly expanding its contractual development and production agency services through a plasmid DNA (pDNA) combination prepared by its Heidelberg plant in Germany. As the demand for plasmid DNA expands rapidly, AGC Biologics is using its 25 years of experience and comprehensive internal analysis to develop it to ensure a shorter and reliable schedule for customers.


       For many different applications, the compound average annual growth rate (cagr) of plasmid dna demand is 20%. for many years, plasmid dna has been widely used in the preparation of dna adjuvants and vaccines and as raw materials for rna drugs and cell-free protein expression platforms. however, in recent years, plasmid dna has become a key to gene therapy applications for lentivirus and adeno-associated virus production and the development of direct gene therapy.


        Patricio Massera, chief executive of AGC Biologics, said:" Our priority has always been to serve our customers through a commitment to sustained innovation. by commercializing the supply of plasmid dna, we are meeting the growing demand. We have the global unified network and experience needed to achieve this expansion. We look forward to working with our customers to help them achieve their goals. For 10 years, the AGC Biologics plant in Heidelberg, Germany, has been working on the preparation of plasmid DNA. now, this factory has completed the plasmid dna preparation process improvement project to support the combination expansion of host and plasmid (low copy and high copy plasmid dna expression system) through a large toolbox in process development (scale from 1 l to 10 l) for the production of high quality plasmid dna. these processes can be easily extended for existing 50 l,100 l,500 l or 1000 l gmp production.


      Agc biologics has microbial plants in heidelberg (germany), copenhagen (denmark) and Chiba (japan) and will soon open a new microbial plant in seattle (usa) with decades of experience in microbial contract development and production agency production, including commercial market supply approved by the u.s. food and drug administration (fda), pdma and ema. These are the best services dedicated to serving as proteins and plasmids for drug substances such as antibody fragments, enzymes, and vaccines.

Introduction to AGC Biologics:
      Agc biologics is the leading global contract development and production agency (cdmo), firmly committed to providing the highest standards of service to customers and partners. The company now has more than 850 employees worldwide. The companyundefineds extensive network covers three continents and has cgmp-compliant factories in seattle, washington state, copenhagen, denmark, heidelberg, germany and Chiba, japan.

     Agc biologics provides a wealth of industry expertise and unique tailored services for mass production of protein therapies from preclinical to commercial production and cgmp production (oriented to mammals and microbes). The companyundefineds extensive integration services include the development of cell lines, bioprocess development, formulation, analytical testing, antibody drug development and binding, cell banking and storage and protein expression - including the companyundefineds proprietary CHEF1® Expression System for mammalian production.